New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 4, 2012
11:34 EDTALXNAlexion:Data show long-term benefits of chronic Soliris therapy in aHUS patients
Alexion Pharmaceuticals announced the presentation of two-year data that highlight the long-term benefits of chronic Soliris, eculizumab, therapy in patients with atypical hemolytic uremic syndrome, aHUS, an ultra-rare genetic disease characterized by thrombotic microangiopathy, TMA, the formation of blood clots in small blood vessels throughout the body. In two pivotal phase 2 studies, which initially enrolled 37 patients, 32 patients entered a long-term extension phase. The data demonstrated that ongoing Soliris treatment for two years was associated with sustained inhibition of complement-mediated TMA, as indicated by a maintained increase in platelet count, and sustained improvement in renal function and TMA event-free status.1,2 The data were presented today at Kidney Week 2012, the annual meeting of the American Society of Nephrology, ASN, in San Diego. Additionally, data presented in a poster session at ASN support early initiation of Soliris therapy regardless of the presence or absence of genetic mutations in patients with aHUS.
News For ALXN From The Last 14 Days
Check below for free stories on ALXN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2014
14:17 EDTALXNAlexion volatility elevated on wide price movement into Q1
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use